In the elderly, life -threatening to 25% in 10 years by respiratory viruses | Health
Although there are more incidents in young children, the respiratory synchronous virus infection (VSR) in the elderly is also severe, the risk of dying. According to a survey by researchers at the Oswaldo Cruz Foundation (Phioocris), the Federal University of Santa Catterina, the GSK Pharmacist and IQVIA Health Information Company, from 2013 to 2023, from 2013 to 2023.
Research shows data. Regardless of the outcome, this ratio is similar to all the elderly people who are admitted to the hospital: 64.2% already has some heart condition, 32% have diabetes and 26.5%, and some pneumopathic.
. Infarction, one of the authors of the study, explains Lessandra Micheli, one of the writers of the study, “infection and three times more risk after infection.”
In the absolute numbers, VSR infection in the elderly is a minor problem, as only government or private units have been recorded in influenza epidemiological surveillance system during this age 3,348 hospital. Leicandra explained that the test of the Synthendic virus has begun to be repeated since 2017, but that most adults with the disease have not been detected to date.
“The child has a large oropharyngeal viral load, so it is easy to diagnose the virus on the swab. It is necessary to have a high viral load of the adult at the beginning of the infection. And when he has a fever, he is usually in the house for 3 or 4 days. He is already hoping for a hospital.” Letendra.
However, the hospital’s admission rate from 2013 to 2023 showed that the hospital’s rate was seven times higher. In addition, 32.6% of patients had to stay in the intensive therapy unit and nearly 70% need respiratory support.
See more
Vaccine
VSR can be avoided with vaccination, but at the moment, two authorized options for use in Brazil are only available only on private network: Abriswo built by GSK and Abriswo.
The Ministry of Health has announced that it has been included in the Unified Health System (SUS) from the second half of this year, but only for pregnant women with the aim of protecting newborns. During the announcement, the government reported that it was studying to expand its immunity to specific elderly groups, but without assessing the deadline.
The recent study of GSK to assess the effect of Arexvy in three seasons of the VSR circulation found that the vaccine was 82.6% and 94% were covered against serious cases in the first year and the protection collected in 31 months was 62.9%.
The data came from the supervision of about 25 thousand elderly in 17 countries.
